top of page
  • Active, not recruiting

NCT03274219 : Phase 1 - bb21217 an Anti-BCMA CAR T Cell Drug Product, in RRMM - CRB-402

Updated: Sep 15, 2022


Study of bb21217 in Multiple Myeloma

Relapsed Refractory Multiple Myeloma


CRB 402 - BB2121

Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM).

Part A of the study will be Dose Escalation followed by Part B, an expansion cohort. Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (bb21217).

Following manufacture of the drug product, subjects will receive lymphodepletion prior to bb21217 infusion. All subjects will then be followed for up to 60 months in Study CRB-402.

All subjects who complete the study, as well as those who withdraw from the study after receiving bb21217 for reasons other than death or meeting the early termination criteria, will be asked to continue to undergo long-term follow-up in a companion study.


bluebird bio Identifier: NCT03274219

Official Title: A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

First Posted : September 6, 2017

Click here for details on


* Idecabtagene Vicleucel

* bb2121

* Bluebird Bio


548 Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Program: Oral and Poster Abstracts

Type: Oral

Session: 704. Cellular Immunotherapies: Cellular Therapies for Myeloma

Hematology Disease Topics & Pathways:

Clinical Trials, Biological, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies

Sunday, December 12, 2021: 4:45 PM


OAB-007 Updated clinical and correlative results from the Phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and/or refractory multiple myeloma -Noopur Raje

#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California


- California: University of California San Francisco

- Florida: Moffitt Cancer Center Tampa

- Georgia: Emory University Atlanta

- Illinois: University of Chicago

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Massachusetts: Massachusetts General Hospital Boston

- Minnesota: Mayo Clinic Rochester Minnesota

- New Jersey: Hackensack University Medical Center

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- Tennessee: Sarah Cannon Research Institute Nashville



United States, California

United States, Florida

United States, Georgia

United States, Illinois

United States, Massachusetts

United States, Minnesota

United States, New Jersey

United States, New York

United States, Tennessee


Posts Archive
bottom of page